Skip to main content

Advertisement

SpringerLink
Log in

Combination Drugs for Treating Obesity

  • Published:
Current Diabetes Reports Aims and scope Submit manuscript

Abstract

Although obesity is a chronic disease like hypertension and diabetes, obesity is not treated with drug combinations as are other chronic diseases. This is because orlistat and sibutramine, the two drugs approved for long-term treatment of obesity, do not result in additive weight loss when combined. This article discusses the history of combination drug therapy for treating obesity, the lessons learned from that experience, and describes the drug combinations now in development. One combination of two standardized dietary herbal supplements that result in clinically significant weight loss is also described. Obesity is poised to enter the era of combination drug therapy, as is now the routine in the treatment of other chronic diseases like hypertension and diabetes. The advent of combination drug therapy for obesity treatment offers hope for increasing the efficacy of obesity pharmacotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Bray GA: Obesity is a chronic, relapsing neurochemical disease. Int J Obes Relat Metab Disord 2004, 28:34–38.

    Article  CAS  PubMed  Google Scholar 

  2. Bray GA: The Battle of the Bulge. Pittsburgh: Dorrance Publishing Co.; 2007.

    Google Scholar 

  3. Health implications of obesity. National Institutes of Health Consensus Development Conference Statement [no authors listed]. Ann Intern Med 1985,103:147–151.

    Google Scholar 

  4. Maffei M, Fei H, Lee GH, et al.: Increased expression in adipocytes of ob RNA in mice with lesions of the hypothalamus and with mutations at the db locus. Proc Natl Acad Sci U S A 1995, 92:6957–6960.

    Article  CAS  PubMed  Google Scholar 

  5. The Obesity Society: What is Obesity? Available at http://www.obesity.org/information/what_is_obesity.asp. Accessed December 2009.

  6. Haddock CK, Poston WS, Dill PL, et al.: Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. Int J Obes Relat Metab Disord 2002, 26:262–273.

    Article  CAS  PubMed  Google Scholar 

  7. Stafford RS, Radley DC: National trends in antiobesity medication use. Arch Intern Med 2003, 163:1046–1050.

    Article  PubMed  Google Scholar 

  8. Malchow-Moller A, Larsen S, Hey H, et al.: Ephedrine as an anorectic: the story of the ‘Elsinore pill’. Int J Obes 1981, 5:183–187.

    CAS  PubMed  Google Scholar 

  9. Dulloo AG: Ephedrine, xanthines and prostaglandin-inhibitors: actions and interactions in the stimulation of thermogenesis. Int J Obes Relat Metab Disord 1993, 17(Suppl 1):S35–S40.

    CAS  PubMed  Google Scholar 

  10. Pasquali R, Cesari MP, Melchionda N, et al.: Does ephedrine promote weight loss in low-energy-adapted obese women? Int J Obes 1987, 11:163–168.

    CAS  PubMed  Google Scholar 

  11. Astrup A, Toubro S, Cannon S, et al.: Thermogenic synergism between ephedrine and caffeine in healthy volunteers: a double-blind, placebo-controlled study. Metabolism 1991, 40:323–329.

    Article  CAS  PubMed  Google Scholar 

  12. Astrup A, Breum L, Toubro S, et al.: The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet. A double-blind trial. Int J Obes Relat Metab Disord 1992, 16:269–277.

    CAS  PubMed  Google Scholar 

  13. Greenway FL: The safety and efficacy of pharmaceutical and herbal caffeine and ephedrine use as a weight loss agent. Obes Rev 2001, 2:199–211.

    Article  CAS  PubMed  Google Scholar 

  14. Hallas J, Bjerrum L, Stovring H, Andersen M: Use of a prescribed ephedrine/caffeine combination and the risk of serious cardiovascular events: a registry-based case-crossover study. Am J Epidemiol 2008, 168:966–973.

    Article  PubMed  Google Scholar 

  15. Greenway FL, Bray GA: Treatment of hypothalamic obesity with caffeine and ephedrine. Endocr Pract 2008, 14:697–703.

    PubMed  Google Scholar 

  16. Weintraub M, Hasday JD, Mushlin AI, Lockwood DH: A double-blind clinical trial in weight control. Use of fenfluramine and phentermine alone and in combination. Arch Intern Med 1984, 144:1143–1148.

    Article  CAS  PubMed  Google Scholar 

  17. Weintraub M, Sundaresan PR, Madan M, et al.: Long-term weight control study. I (weeks 0 to 34). The enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo. Clin Pharmacol Ther 1992, 51:586–594.

    CAS  PubMed  Google Scholar 

  18. Atkinson RL, Blank RC, Schumacher D, et al.: Long-term drug treatment of obesity in a private practice setting. Obes Res 1997, 5:578–586.

    CAS  PubMed  Google Scholar 

  19. Greenway FL, Ryan DH, Bray GA, et al.: Pharmaceutical cost savings of treating obesity with weight loss medications. Obes Res 1999, 7:523–531.

    CAS  PubMed  Google Scholar 

  20. Connolly HM, Crary JL, McGoon MD, et al.: Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997, 337:581–588.

    Article  CAS  PubMed  Google Scholar 

  21. Ryan DH, Bray GA, Helmcke F, et al.: Serial echocardiographic and clinical evaluation of valvular regurgitation before, during, and after treatment with fenfluramine or dexfenfluramine and mazindol or phentermine. Obes Res 1999, 7:313–322.

    CAS  PubMed  Google Scholar 

  22. Smith SR, Prosser WA, Donahue DJ, et al.: Lorcaserin (APD356), a selective 5-HT(2C) agonist, reduces body weight in obese men and women. Obesity (Silver Spring) 2009,17:494–503.

    Article  CAS  Google Scholar 

  23. Greenway FL: Clinical studies with phenylpropanolamine: a meta-analysis. Am J Clin Nutr 1992, 55:203S–205S.

    CAS  PubMed  Google Scholar 

  24. Kernan WN, Viscoli CM, Brass LM, et al.: Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med 2000, 343:1826–1832.

    Article  CAS  PubMed  Google Scholar 

  25. Collipp PJ: The treatment of exogenous obesity by medicated benzocaine candy: a double-blind placebo study. Obes Bariatr Med 1981, 10:123–125.

    Google Scholar 

  26. Greenway F, Herber D, Raum W, Morales S: Double-blind, randomized, placebo-controlled clinical trials with non-prescription medications for the treatment of obesity. Obes Res 1999, 7:370–378.

    CAS  PubMed  Google Scholar 

  27. Sari R, Balci MK, Cakir M, et al.: Comparison of efficacy of sibutramine or orlistat versus their combination in obese women. Endocr Res 2004, 30:159–167.

    Article  CAS  PubMed  Google Scholar 

  28. Knowler WC, Barrett-Connor E, Fowler SE, et al.: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393–403.

    Article  CAS  PubMed  Google Scholar 

  29. Sari R, Balci MK, Coban E, Yazicioglu G: Comparison of the effect of orlistat vs orlistat plus metformin on weight loss and insulin resistance in obese women. Int J Obes Relat Metab Disord 2004, 28:1059–1063.

    Article  CAS  PubMed  Google Scholar 

  30. Aronne LJ, Halseth A, Burns C, et al.: Enhanced weight loss following co-administration of pramlintide with sibutramine or phentermine in obese subjects. Obesity (Silver Spring) 2010, in press.

  31. Bray GA, Hollander P, Klein S, et al.: A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes Res 2003, 11:722–733.

    Article  CAS  PubMed  Google Scholar 

  32. VIVUS, Inc. Press Releases. Available at http://ir.vivus.com/releases.cfm. Accessed December 2009.

  33. Mitchell JE, Morley JE, Levine AS, et al.: High-dose naltrexone therapy and dietary counseling for obesity. Biol Psychiatry 1987, 22:35–42.

    Article  CAS  PubMed  Google Scholar 

  34. Jain AK, Kaplan RA, Gadde KM, et al.: Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms. Obes Res 2002, 10:1049–1056.

    Article  CAS  PubMed  Google Scholar 

  35. Anderson JW, Greenway FL, Fujioka K, et al.: Bupropion SR enhances weight loss: a 48-week double-blind, placebo-controlled trial. Obes Res 2002, 10:633–641.

    Article  CAS  PubMed  Google Scholar 

  36. •• Greenway FL, Whitehouse MJ, Guttadauria M, et al.: Rational design of a combination medication for the treatment of obesity. Obesity (Silver Spring) 2009, 17:30–39. This paper describes the preclinical mechanistic studies of this combination drug. obesity therapy followed by a pilot clinical trial.

    Article  CAS  Google Scholar 

  37. • Greenway FL, Dunayevich E, Tollefson G, et al.: Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo. J Clin Endocrinol Metab 2009, 94:4898–4906. This paper describes the phase 2 trial of this obesity drug combination defining the dose-response relationships.

    Article  CAS  PubMed  Google Scholar 

  38. Orexigen Therapeutics 2010 Press Releases. Available at http://ir.orexigen.com/phoenix.zhtml?c=207034&p=irol-news&nyo=0. Accessed December 2009.

  39. Gadde KM, Franciscy DM, Wagner HR 2nd, Krishnan KR: Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA 2003, 289:1820–1825.

    Article  CAS  PubMed  Google Scholar 

  40. Li Z, Maglione M, Tu W, et al.: Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 2005, 142:532–546.

    CAS  PubMed  Google Scholar 

  41. Gadde KM, Yonish GM, Foust MS, Wagner HR: Combination therapy of zonisamide and bupropion for weight reduction in obese women: a preliminary, randomized, open-label study. J Clin Psychiatry 2007, 68:1226–1229.

    Article  CAS  PubMed  Google Scholar 

  42. Heymsfield SB, Greenberg AS, Fujioka K, et al.: Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA 1999, 282:1568–1575.

    Article  CAS  PubMed  Google Scholar 

  43. Smith SR, Aronne LJ, Burns CM, et al.: Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity. Diabetes Care 2008, 31:1816–1823.

    Article  PubMed  Google Scholar 

  44. • Roth JD, Roland BL, Cole RL, et al.: Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies. Proc Natl Acad Sci U S A 2008, 105:7257–7262. This paper describes the preclinical mechanistic studies in rodents.

    Article  CAS  PubMed  Google Scholar 

  45. •• Ravussin E, Smith SR, Mitchell JA, et al.: Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. Obesity (Silver Spring) 2009, 17:1736–1743. This paper describes the pilot clinical trial of this obesity drug combination.

    Article  CAS  Google Scholar 

  46. Hendricks EJ, Rothman RB, Greenway FL: How physician obesity specialists use drugs to treat obesity. Obesity (Silver Spring) 2009, 17:1730–1735.

    Article  Google Scholar 

  47. Rothman RB: Treatment of obesity with “combination” pharmacotherapy. Am J Ther 2009 May 19 [Epub ahead of print].

  48. Oben J, Kuate D, Agbor G, et al.: The use of a Cissus quadrangularis formulation in the management of weight loss and metabolic syndrome. Lipids Health Dis 2006, 5:24.

    Article  PubMed  Google Scholar 

  49. Oben JE, Enyegue DM, Fomekong GI, et al.: The effect of Cissus quadrangularis (CQR-300) and a Cissus formulation (CORE) on obesity and obesity-induced oxidative stress. Lipids Health Dis 2007, 6:4.

    Article  PubMed  Google Scholar 

  50. • Oben JE, Ngondi JL, Momo CN, et al.: The use of a Cissus quadrangularis/Irvingia gabonensis combination in the management of weight loss: a double-blind placebo-controlled study. Lipids Health Dis 2008, 7:12. This paper describes a combination of two standardized dietary herbal supplements that show a clinically significant weight loss.

    Article  PubMed  Google Scholar 

Download references

Disclosure

Dr. Frank L. Greenway is a medical consultant on naltrexone, zonisamide, and bupropion for Orexigen Therapeutics, Inc. Dr. George A. Bray has been a consultant for VIVUS Pharmaceuticals.

Author information

Authors and Affiliations

  1. Pennington Biomedical Research Center, Louisiana State University System, 6400 Perkins Road, Baton Rouge, LA, 70808, USA

    Frank L. Greenway & George A. Bray

Authors
  1. Frank L. Greenway
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. George A. Bray
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Frank L. Greenway.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Greenway, F.L., Bray, G.A. Combination Drugs for Treating Obesity. Curr Diab Rep 10, 108–115 (2010). https://doi.org/10.1007/s11892-010-0096-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11892-010-0096-4

Keywords

Search

Navigation